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A B S T R A C T
The aim of this study was to determine the prevalence of anxiety and depression symptoms in outpatients with treated
asthma and to determine the influence of anxiety and depression symptoms on lung function and asthma symptoms. The
study was conducted in the pulmonary clinic of the Department of Pulmonary Diseases, Osijek University Hospital Cen-
tre, on 200 outpatients with asthma, aged 18–50 years, of which there were 65.5% women and 35.5% men. Each patient
underwent a clinical examination with an extensive anamnesis and lung auscultation. The lung function was tested by
spirometry. Demographic data and data on general and socioeconomic characteristics were evaluated using a question-
naire created internally for the purposes of this research, psychological status was assessed by HAD questionnaire, and Q
test was used as a measure of asthma control. Based on the HAD questionnaire, 44.5% of asthma patients met the criteria
for anxiety, and 24.5% of asthma patients met the criteria for depression. There was no significant correlation between
asthma symptoms and the degree of anxiety or depression, while the pulmonary function of asthma patients negatively
correlated with the degree of anxiety and depression. Pulmonary function in asthma patients with symptoms of anxiety
and depression was significantly poorer than in asthma patients without anxiety and/or depression symptoms. The re-
sults show that among asthma patients there are large number of those who have symptoms of anxiety and depression.
Asthma patients with symptoms of anxiety and depression have poorer lung function than patients with only asthma
symptoms, however there is no significant correlation between the lung function and symptoms of asthma. We have con-
firmed that patients with anxiety symptoms visit general practitioners or EMS significantly more when compared to pa-
tients with depression symptoms.
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Introduction
The prevalence of asthma is increasing worldwide, es-
pecially in Western and industrialized countries and it is
expected that in the next twenty years the number of pa-
tients could increase for another hundred million1. In
particular, it is rising among children and adolescents2,3.
Asthma is a very common and complex respiratory dis-
ease that occurs as a result of the interaction of genetic,
environmental, social and psychological factors. In the
pathogenesis of asthma, oxidative stress appears to play
an important role and existence of an oxidant/antioxi-
dant imbalance is evident4. The asthmatic patients more
frequently perceived harmful ecological factors in their
environment and regarded them significant for the oc-
currence of their disease5,6. Furthermore, studies show
that patients with asthma have an increased risk of de-
veloping psychiatric disorders7,8,10. The association be-
tween asthma and emotional factors has been researched
for a long time. Numerous studies suggest that there is a
correlation between asthma and specific mental disor-
ders, particularly anxiety and depression, but it is still
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not clear whether having asthma is a risk factor for de-
veloping anxiety and depression, or if psychiatric disor-
ders increase the risk of developing asthma. Children
and adolescents with asthma have twice as high risk of de-
veloping one or more anxiety or depressive disorders11,12.
It is believed that psychological factors, such as personal-
ity characteristics may be important, and that they pri-
marily affect the development and clinical expression of
asthma. Asthma symptoms are of a great importance for
both patients and doctors, because medical decisions are,
amongst other, based on the patient’s condition and re-
ported symptoms. Patients seem to be satisfied with
asthma control that does not correspond to suppression
of symptoms, whereas physicians neglect patients’ emo-
tional problems and the impact asthma has on everyday
life. The differences in the perception of asthma may re-
flect differences in beliefs about health. Physicians see
health as an absence of symptoms, whereas patients re-
gard being healthy as »being able«13. Because of the over-
lap between asthma, anxiety (shortness of breath, rapid
heartbeat) and depression symptoms (insomnia, anxi-
ety), they can be misinterpreted which in turn could lead
to unrecognized and untreated anxiety and depressive
disorders, which affects treatment strategies and causes
poorer treatment outcome. There is contradictory data if
patients with asthma and comorbid mental disorders
have more symptoms of asthma and if coexistent mental
disorders have a greater negative effect on lung function
and make it worse than the one observed in the patients
who suffer only from asthma. If so, this could result in an
increased need for health service14–17.
Patients and Methods
Included in the study were 200 outpatients with as-
thma who came to regular examination. The patients
were between ages 18–50, of both genders and from both
rural and urban geographies. During the study, all pa-
tients were treated with anti-inflammatory, symptomatic
medications or their combinations. We excluded patients
with respiratory diseases other than asthma and the pa-
tients with diseases of other organ systems, such as dia-
betes, autoimmune diseases, cancer and other serious ill-
nesses.
Each patient was subjected to a detailed anamnesis
and subjective symptoms were evaluated. We evaluated
daily and nocturnal asthma symptoms like cough, short-
ness of breath, wheezing, production of mucus and wak-
ing up or walking at night. Based on the reported subjec-
tive symptoms of asthma and information about taking
the recommended therapy, patients were classified into
four groups according to intensity, as defined by GINA1:
intermittent asthma, mild persistent asthma, moderate
persistent and severe persistent asthma. After evaluat-
ing severity of symptoms, clinical examination with lung
auscultation was made. Auscultation of the lungs was
used to distinguish three groups of patients according to
the severity of symptoms such as: normal breathing, im-
paired breathing, noise and bronchial sounds, whistles
and prolonged expiration.
Pulmonary function of asthma patients was mea-
sured by spirometry which was repeated three times.
The evaluation was based on the best values of 3 accept-
able attempts before, and 20 minutes after the applica-
tion of salbutamol 0.4 mg through inhalation, which is
equivalent to the standard test. Evaluated spirometry
parameters were: forced vital capacity (FVC), forced ex-
piratory volume in 1st second (FEV1), ratio of forced expi-
ratory volume and vital capacity x100 (Tiffeneau index)
and the peak expiratory flow rate (PEF). Obstructive
ventilatory disorder was considered if the results were
expressed as the standard value in a relation to the refer-
ence according to ECCS/ERS standards18.
After examination and spirometry each patient was
given four self-assessment instruments.
General socio-demographic and psychosocial data were
gathered using a questionnaire about general and psy-
chosocial data, made internally for this study. To esti-
mate the severity of asthma symptoms over a period of
seven days before the start of the research, we used a »Q
score« questionnaire19. It is a short patient focused mor-
bidity index consisting of four questions in relation to the
past week: 1. How many times last week did you lose air
and feel pressure in your chest? 2. How many nights did
you wake up because of asthma? 3. How many times this
week has asthma prevented you from normal activity? 4.
How many times have you used your inhaler? Each ques-
tion was measured with scores from 0–2, depending on
the rounded 1 of 3 options. The result of the scale was ex-
pressed as a sum ranging from 0–8. With the »Q score« a
low total score indicates a greater control of asthma
symptoms – Q value was divided into scores less than,
equal to, or greater than 4 of 4. A score less than or equal
to 4, indicates a good control of asthma symptoms, whilst
greater than 4 indicate poor control of asthma symp-
toms. Hospital Anxiety and Depression scale (HAD)20
was used to measure anxiety and depression symptoms.
It consists of 14 claims, of which 7 are related to anxiety
and 7 to depression. The value 7 or less on the HAD scale
was taken as normal, 8–10 indicated presence of anxiety
and depression symptoms, and a value of 11 or more a de-
finitive presence of anxiety and depression symptoms.
To describe numerical figures, we used basic mea-
sures of the medium and scattering. A normality of dis-
tribution of the observed numerical variables was tested
by Kolmogorov-Smirnov’s test. Categorial variables were
described in absolute and relative frequencies. Kruskal-
-Wallis’s test was used for comparing more than two in-
dependent groups. Differences between categorical vari-
ables were tested with c2-test or Fisher’s exact test.
Internal reliability coefficient of each questionnaire was
demonstrated with Cronbach’s coefficient. For assessing
the importance of the results, the level of the importance
of alpha=0.05 was chosen. To compile the results we
used the software Statistica for Windows 2005 (version
7.1, StatSoft Inc., Tulsa, OK, USA).
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Results
The testing was conducted on 200 patients, mean age
35.8 years, ranging from 18 to 50 years, 34.5% male and
65.5% female patients. 54% of the patients were from an
urban area. Most patients (79.5%) were non-smokers,
and 20.5% of patients were current smokers. Consi-
dering duration of asthma, patients were divided into
three groups (up to 2 years, from 2 to 5 years and 5 years
and more) and the majority of patients had been treated
for asthma for more than 5 years (44.5%). The majority
of the patients, 42.5% of them, had intermittent asthma,
33.5% had mild persistent, 19.5% moderate persistent,
and 4.5% had severe persistent asthma (Figure 1). In the
last week of testing, there were no asthma symptoms in
45.5% of the patients. The most common symptom, in
both men and women, was shortness of breath (30%),
and 11.5% of the patients had early morning or persis-
tent dry cough. Other symptoms were present in 24.5%
of the patients (Table 1). Considering duration of as-
thma, the most commonly reported symptoms were shor-
tness of breath and wheezing in all three patient groups.
However, it was not proven that the presence of certain
symptoms in correlation to duration of asthma was sta-
tistically significant (p=0.070) (Table 2). Considering
auscultatory findings, 75% had normal breathing noise,
11.5% had decreased breathing noise, while 14% of the
patients had bronchial noises, whistles and prolonged ex-
piration. Comparison of auscultatory findings with the
most common symptoms of asthma in the last week of re-
search, showed that 35.7% of patients with shortness of
breath, had also bronchial sounds, whistles and pro-
longed expiration and 39.3% of patients who did not have
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TABLE 1
THE MOST COMMON SYMPTOMS OF ASTHMA DISTRIBUTED BY GENDER IN THE LAST WEEK








Early morning or persistent cough 11 (15.9) 12 (9.2) 23 (11.5)
0.252
Shortness of breath (wheezing...) 26 (37.7) 34 (26) 60 (30)
Pressure in the chest 3 (4.3) 9 (6.9) 12 (6)
Creating sewage which is difficult to release 3 (4.3) 8 (6.1) 11 (5.5)
Wake-up or walk at night 1 (1.4) 2 (1.5) 3 (1.5)
No symptoms 25 (36.2) 66 (50.4) 91 (45.5)
Total 69 (100) 131 (100) 200 (100)
*c2-test
Fig. 1. Distribution of the patients by asthma severity rate based
on the symptoms.
TABLE 2
DISTRIBUTION OF THE PATIENTS CONSIDERING DURATION OF ASTHMA AND MOST COMMON SYMPTOMS










Early morning or persistent cough 12 (16.9) 1 (2.5) 10 (11.2) 23 (11.5)
0.070
Shortness of breath (wheezing...) 23 (32.4) 9 (22.5) 28 (31.5) 60 (30)
Pressure in the chest 4 (5.6) 6 (15) 2 (2.2) 12 (6)
Creating sewage difficult to release 2 (2.8) 2 (5) 7 (7.9) 11 (5.5)
Wake-up or walk at night 0 1 (2.5) 2 (2.2) 3 (1.5)
No symptoms 30 (42.3) 21 (52.5) 40 (44.9) 91 (45.5)
Total 71 (100) 40 (100) 89 (100) 200 (100)
*c2-test
asthma symptoms, had bronchial sounds, whistles and
prolonged expiration, too. Among the functional tests on
the entire group of patients, spirometry testing was done
with special emphasis on the parameters indicating ob-
structive disorders of ventilation: vital capacity (VC),
forced vital capacity (FVC), forced expiratory volume in
first second (FEV1), Tiffeneau index and the highest ex-
piratory flow (PEF). Disturbance of obstructive ventila-
tion was divided on the basis of the measured FEV1 to a:
lower degree of obstruction (60–80% of baseline), inter-
mediate level (40–59% baseline) and high level (less than
40% of baseline). Most patients had normal spirometry
and 17.5% of the patients had obstructive interference,
of which 8.5% had lower degree of obstruction, 7.5% ob-
struction of intermediate level and only 1.5% of patients
had high level obstruction. The presence of anxiety and
depression symptoms in asthma patients measured by
HAD scale proved that anxiety was present in 44.5% of
patients, of which 25% had proved anxiety and 19.5%
had questionable anxiety. Also it was found that 24.5% of
the patients had symptoms of depression, out of which
13% of patients had questionable and 11.5% proved de-
pression (Figure 2). Due to asthma symptoms 37.5% of
the patients visited a GP/ERS or demanded hospital ser-
vices during the last week of testing, out of which 54.5%
suffering from anxiety. The difference was statistically
significant (p=0.017) in comparison to patients with de-
pression where we did not confirm the relationship be-
tween depression and frequency of visiting the GP/ERS
or demanding hospital services (p=0.836) (Table 3). The
aim of this study was to determine the influence of anxi-
ety and depression symptoms on the type, frequency and
intensity of asthma symptoms with the degree of anxiety
or depression, which did not prove statistically signifi-
cant (Table 4 and 5). The research found that with 52%
of the patients with anxiety and depression symptoms,
there were no asthma symptoms and most commonly re-
ported symptoms were shortness of breath and wheez-
ing, early morning or persistent cough. The difference in
the prevalence of individual symptoms of asthma and the
level of anxiety and depression did not prove statistically
significant (p=0.429 for anxiety and p=0.414 for depres-
sion). In patients with asthma and anxiety symptoms,
measured values of vital capacity, forced vital capacity
and forced expiratory volume in 1st second, and PEF
were significantly lower (p<0.001 and p=0.007) than in
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TABLE 3
VISITING THE DOCTOR OR EMS BECAUSE OF ASTHMA
Asthma










Not present 77 (61.6) 34 (45.3) 111 (55.5)
0.017Questionable 17 (13.6) 22 (29.3) 39 (19.5)
Present 31 (24.8) 19 (25.3) 50 (25)
Depression
Not present 96 (76.8) 55 (73.3) 151 (75.5)
0.836
Questionable 15 (12) 11 (14.7) 26 (13)
Present 14 (11.2) 9 (12) 23 (11.5)
Total 125 (100) 75 (100) 200 (100)
TABLE 4











Early morning or persistent cough 12 (10.8) 3 (7.7) 8 (16.0) 23 (11.5)
0.429
Shortness of breath (wheezing...) 37 (33.3) 10 (25.6) 13 (26.0) 60 (30)
Pressure in the chest 9 (8.1) 3 (7.7) 0 12 (6)
Creating sewage which is difficult to release 7 (6.3) 1 (2.6) 3 (6.0) 11 (5.5)
Wake-up or walk at night 2 (1.8) 1 (2.6) 0 3 (1.5)
No symptoms 44 (39.6) 21 (53.8) 26 (52.0) 91 (45.5)
Total 111 (100) 39 (100) 50 (100) 200 (100)
*c2-test
Fig. 2. The distribution of the patients according to the presence
of anxiety and depression.
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TABLE 5











Early morning or persistent cough 14 (9.3) 6 (23.1) 3 (13) 23 (11.5)
0.414
Shortness of breath (wheezing...) 48 (31.8) 6 (23.1) 6 (26.1) 60 (30)
Pressure in the chest 12 (7.9) 0 0 12 (6)
Creating sewage which is difficult to release 8 (5.3) 1 (3.8) 2 (8.7) 11 (5.5)
Wake-up or walk at night 3 (2) 0 0 3 (1.5)
No symptoms 66 (43.7) 13 (50) 12 (52.2) 91 (45.5)
Total 151 (100) 26 (100) 23 (100) 200 (100)
*c2-test
TABLE 6










Sv (SD)* Sv (SD)* Sv (SD)*
Vital capacity (VC) 109.66 (13.4) 105.43 (15.2) 95.9 (19.7) <0.001
Forced vital capacity (FVC) 111.27 (13.7) 106.46 (16.6) 96.84 (21.3) <0.001
Forced expiratory volume in 1st (FEV1) 105.24 (18.6) 98.05 (21.3) 88.14 (27.9) <0.001
TIFF % (FEV1/VC) 97.09 (10.9) 94 (12.9) 91.94 (16.3) 0.256
Peak expiratory flow (PEF) 103.22 (44.9) 91.74 (19.4) 87.04 (29.3) 0.007
TABLE 7











Sv (SD)* Sv (SD)* Sv (SD)*
MALE
Vital capacity (VC) 107.57 (15.5) 106.62 (8.9) 98.83 (18.13) 0.193
Forced vital capacity (FVC) 108.80 (16.10) 107.80 (11.73) 100.05 (19.59) 0.221
Forced expiratory volume in 1st second (FEV1) 99.17 (21.3) 99.00 (15.15) 89.55 (31.79) 0.313
TIFF % (FEV1/VC) 92.85 (12.30) 94.75 (11.15) 88.77 (31.79) 0.529
Peak expiratory flow (PEF) 107.00 (44.8) 95.75 (15.37) 88.83 (34.06) 0.450
FEMALE
Vital capacity (VC) 110.63 (12.31) 104.61 (18.54) 94.37 (20.74) <0.001
Forced vital capacity (FVC) 112.40 (12.46) 105.95 (19.57) 95.03 (22.40) <0.001 t
Forced expiratory volume in 1st second (FEV1) 108.03 (16.69) 97.39 (25.10) 87.34 (26.12) <0.001
TIFF % (FEV1/VC) 99.04 (9.79) 93.47 (14.25) 93.72 (16.12) 0.254
Peak expiratory flow (PEF) 101.47 (20.18) 88.95 (21.66) 86.03 (26.92) 0.008
*Standard deviation; †Kruskal Wallis test
the patients without the symptoms of anxiety (Table 6),
and especially in women (Table 7). In addition, we found
that patients with anxiety symptoms tended to have
higher asthma levels, but the difference was not statisti-
cally significant (p=0.067). It is evident that all the spi-
rometry parameters were significantly lower (p<0.001
and p=0.006) in patients with depression, comparing to
patients without depression (Table 8). Due to the fact
that all spirometric parameters were significantly lower
in each stage of anxiety and depression, the lung func-
tion was significantly worse among the patients with
anxiety and depression symptoms, unlike among the pa-
tients without these symptoms. Based on the results ob-
tained by Q test we did not found a statistically signifi-
cant difference between the parameters of Q test and the
degree of anxiety, while there was a significant difference
in the number of patients who were left without air last
week (p=0.031) (Figure 3) and number of inhaler use for
the past week (p=0.006) in relation to the degree of de-
pression (Figure 4). Observing the relationship between
asthma severity and anxiety, it is evident that differences
exist but are not statistically significant. Depression, on
the other hand showed a statistically significant differ-
ence (p=0.011) in all patients (Table 9).
Discussion
The association of anxiety and depression with as-
thma has been confirmed in numerous studies7–9 as well
as that it already occurs in childhood and adolescen-
ce10–12,15,21–24. Psychiatric disorders were significantly mo-
re frequent in asthmatics than in non-asthmatic popula-
tion25,26, and the ratio of various psychiatric disorders,
particularly anxiety and depression, according to various
researchers varied and range from 9% to 65%17,27–29. The
results of this study show a high proportion of anxiety
and depression symptoms in patients with diagnosed
asthma, which is consistent with the results of other
studies16,19,30–37. The study confirmed that asthma pa-
tients with anxiety symptoms visit the doctor or demand
emergency care more often because of asthma symptoms,
which is associated with greater use of bronchodilators
and corticosteroids that significantly increases, both di-
rect and indirect health care costs. According to the
research8,24,33,38,39 there is a strong correlation between
respiratory symptoms and indicators of psychological
status. It is believed that, due to the partial overlapping
of symptoms, asthma patients with psychiatric disorder
have significantly more respiratory symptoms. Hyper-
ventilation is known as a common indicator of physical
anxiety40. However, this research did not confirm a sta-
tistically significant difference in the prevalence of indi-
vidual symptoms and the degree of anxiety and depres-
sion. The results showed that the degree of asthma-sever-
ity is positively associated with studied mental disorders,
particularly in women. The thesis that the more severe
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TABLE 8










Sv (SD)* Sv (SD)* Sv (SD)*
Vital capacity (VC) 108.4 (13.8) 101.1 (16.9) 90.9 (22.8) 0.001
Forced vital capacity (FVC) 109.8 (14.4) 102.9 (19.4) 90.9 (24.0) 0.001
Forced expiratory volume in 1st (FEV1) 103.5 (19.5) 92.2 (27.0) 81.9 (28.5) <0.001
TIFF % (FEV1/VC) 96.5 (11.9) 91.6 (15.2) 90.6 (16.0) 0.103
Peak expiratory flow (PEF) 101.1 (39.9) 84.3 (26.8) 84.4 (30.9) 0.006
Fig. 3. The difference in the number of patients who left without
air according to the q test for anxiety and depression.
Fig. 4. The difference in the number of patients who left used in-
haler according to the q test for anxiety and depression.
asthma is associated with mental disorders is also sup-
ported by Garden and Ayres42. Lung function, measured
by spirometry, with all parameters in this study is signifi-
cantly worse in severe persistent asthma, and shows a
significant association with asthma severity score by
GINA1,33,43, while the duration of asthma was not found
as a statistically significant correlate. Conolly and co.43
show that the highest lung capacity becomes lower at
each higher level of treatment, what suggests that these
patients may have irreversible damage – changes on
lungs were already noticed. We also confirmed that the
pulmonary function is significantly worse for patients
that have present anxiety and depression (significantly
higher for women), than for patients without a psychiat-
ric disorder, which is consistent with some studies33,
while other studies indicate the opposite and that is a
strong relationship between respiratory symptoms and
psychological status indicators, but a negative correla-
tion with pulmonary function8,34,44. Moy45 also states that
measurements of lung function are not predictors of
quality of life, while taking relivers and intensity of
symptoms as dyspnea, wheezing and coughing are signif-
icant predictors of quality of life. The goal of asthma
treatment is to achieve and maintain good disease con-
trol with minimal side effects associated with therapy.
However, numerous studies have shown that despite
available effective drugs, control of the disease can be
achieved only in some patients46. One possible reason for
poor disease control and poor patient compliance and
failure to comply with the recommended therapy is often
caused by the accompanying anxiety or depression and
therefore we should act on the early recognition of anxi-
ety and depression symptoms and thus that the question-
naires on asthma control should include the questions
about possible mental disorders. Consequently to that,
the appearance and intensity of asthma symptoms will
be lower, pulmonary function in patients with asthma
will be the better what will contribute to better asthma
control and improvement of their quality of life.
Conclusion
In patients with asthma, there are a significant num-
ber of patients with anxiety and depression symptoms.
Patients with anxiety and depression symptoms have a
more severe level of asthma. However, we did not con-
firm statistically significant difference between asthma
symptoms and the degree of anxiety and depression.
Visits to the GP or ERS because of asthma symptoms
were significantly more frequent in patients with anxiety
symptoms. All spirometric parameters showed that the
pulmonary function is worse in patients with anxiety and
depression. Patients with anxiety and depression have
poorer disease control measured by Q test, than patients
with asthma without these disorders, but the results
were not statistically significant. The prevalence of pa-
tients with anxiety and depression symptoms in asthma
is significant and has a negative impact on symptoms
and lung function in asthma patients, resulting in poorer
disease control and increased use of health care. There-
fore, it is crucial that physicians in the evaluation of the
disease control and the evaluation of treatment strate-
gies take into account the impact of negative moods and
reduce undeniable negative impact on the quality of life
of asthma patients. It is necessary that questionnaires
about asthma include questions about possible psycho-
logical problems, as they may be one of the most promis-
ing strategies, not only to improve suppression of as-
thma, but health in general. Certainly we know that the
quality of life of all asthmatics, especially the ones with
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TABLE 9











Intermittent asthma 52 (46.8) 16 (41) 17 (34) 85 (42.9)
0.067
Mild persistent asthma 39 (35.1) 12 (30.8) 16 (32) 67 (33.5)
Moderate persistent asthma 19 (17.1) 9 (23.1) 11 (22) 39 (19.5)
Severe persistent asthma 1 (0.9) 2 (5.1) 6 (12) 9 (4.5)











Intermittent asthma 71 (47) 9 (34.6) 5 (21.7) 85 (42.5)
0.011
Mild persistent asthma 50 (33.1) 10 (38.5) 7 (30.4) 67 (33.5)
Moderate persistent asthma 27 (17.9) 5 (19.5) 7 (30.4) 39 (19.5)
Severe persistent asthma 3 (2) 2 (7.7) 4 (17.4) 9 (4.5)
Total 151 (100) 26 (100) 23 (100) 200 (100)
comorbid anxiety or depression, is significantly reduced
because they are less tolerant to physical exertion and
mental stress47. It is not yet known how the treatment of
anxiety and depression symptoms can affect asthma con-
trol and quality of life for these patients and further lon-
gitudinal studies are required.
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PREVALENCIJA ANKSIOZNIH I DEPRESIVNIH POREME]AJA U BOLESNIKA S ASTMOM I
UTJECAJ NA SIMPTOME I PLU]NU FUNKCIJU U BOLESNIKA S ASTMOM
S A @ E T A K
Cilj ove studije je utvrditi u~estalost simptoma anksioznosti i depresije u bolesnika s astmom koji su ambulantno
lije~eni te utvrditi utjecaj simptoma anksioznosti i depresije na plu}nu funkciju i simptome astme. Studija je provedena
u pulmolo{koj ambulanti Odjela za plu}ne bolesti KBC Osijek na 200 ambulantno lije~enih bolesnika s astmom u dobi
od 18–50 godina, od toga je bilo 65,5 % `ena i 45,5% mu{karaca. Svakom bolesniku u~injen je klini~ki pregled s op-
se`nom anamnezom i auskultacijom plu}a. Funkcija plu}a ispitana je metodom spirometrije. Demografski podaci i po-
daci o op}im i socioekonomskim obilje`jima ispitani su koriste}i interno napravljen upitnik za potrebe ovog istra`iva-
nja, a psiholo{ki status je ocijenjen HAD upitnikom, te je kao mjera kontrole astme kori{ten Q test. Na osnovu HAD
upitnika 44,5% bolesnika s astmom ima kriterije za anksioznost, a 24,5% bolesnika ima kriterije za depresiju. Nije
dokazana zna~ajna povezanost simptoma astme sa stupnjem anksioznosti ili depresije, dok je plu}na funkcija bolesnika
s astmom negativno povezana sa stupnjem anksioznosti i depresije, odnosno plu}na funkcija bolesnika s astmom i
simptomima anksioznosti i depresije je zna~ajno lo{ija nego u bolesnika s astmom, a bez simptoma anksioznosti i /ili
depresije. Rezultati pokazuju da u bolesnika s astmom postoji velik udio bolesnika koji imaju i simptome anksioznosti i
depresije. Bolesnici s astmom i simptomima anksioznosti i depresije imaju lo{iju plu}nu funkciju nego bolesnici sa samo
simptomima astme, dok zna~ajna povezanost s pojavom pojedinih simptoma astme nije potvr|ena. Potvrdili smo da
bolesnici sa simptomima anksioznosti zna~ajno ~e{}e posje}uju lije~nika op}e prakse ili HMP u odnosu na bolesnike sa
simptomima depresije.
